Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC
Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes
Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma
Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management
2 Commerce Drive
Cranbury, NJ 08512